Patents Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Serv
-
Publication number: 20140004135Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.Type: ApplicationFiled: March 14, 2013Publication date: January 2, 2014Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, GLOBEIMMUNE, INC.Inventors: GLOBEIMMUNE, INC., The United States of America, as represented by the Secretary, Department of Health and Human Services
-
Publication number: 20130345391Abstract: Composite probes for super resolution optical techniques using super resolution via transiently activated quenchers (STAQ) include a donor moiety and an acceptor moiety joined by a linker, wherein the acceptor moiety, when excited by incident radiation, is excited to a state which, for example, absorbs in the donor emission region, such that the acceptor moiety in its excited state quenches at least a portion of the donor moiety emission. Other transiently activated quenching mechanisms and moieties could accomplish the same task by reducing donor population. Also disclosed are methods for irradiating a selected region of a target material including the composite probe, wherein the composite probe enables improved resolution by point spread function modification and/or nanoscale chemical reactions.Type: ApplicationFiled: August 15, 2013Publication date: December 26, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Jay R. Knutson, Gary L. Griffiths
-
Publication number: 20130331460Abstract: Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, methods for using the chrysophaentin compounds, and methods for synthesizing the chrysophaentin compounds are disclosed. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.Type: ApplicationFiled: February 24, 2012Publication date: December 12, 2013Applicants: UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVInventors: Carole A. Bewley, Peter Wipf
-
Publication number: 20130316957Abstract: Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided.Type: ApplicationFiled: August 1, 2013Publication date: November 28, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Nadya Tarasova, Michael Dean, Hong Lou
-
Publication number: 20130316947Abstract: The present disclosure is generally related to methods of using the secretory protein SCGB3A2 for promoting lung development and treating lung disease. Some embodiments are, for example, methods for treating and inhibiting the development of neonatal respiratory distress. Other embodiments are methods of promoting lung development in damaged or diseased lungs. Also disclosed are methods for inhibiting lung damage due to anti-cancer agents.Type: ApplicationFiled: August 5, 2013Publication date: November 28, 2013Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human ServInventors: Shioko Kimura, Reiko Kurotani
-
Publication number: 20130274203Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.Type: ApplicationFiled: September 14, 2011Publication date: October 17, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventor: Dhanalakshmi Chinnasamy
-
Publication number: 20130273111Abstract: The polynucleotide encoding the antigen Wb123 from the filarial nematode Wuchereria bancrofti, the major causative organism of lymphatic filariasis is provided, along with the polypeptide encoded by the polynucleotide. Methods for making the WM23 antigen, recombinant vectors encoding the Wb123 polynucleotide, and methods of detection of the Wb123 antigen through luciferase immunprecipitation, ELISA and other detection systems are also provided.Type: ApplicationFiled: October 31, 2011Publication date: October 17, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Thomas B. Nutman, Doran Fink, Joseph Kubofcik, Peter D. Burbelo
-
Publication number: 20130274591Abstract: The present application discloses a guidewire for magnetic resonance imaging with a single channel design to reduce complexity and to provide conspicuous tip visibility under MRI. In one embodiment, a guidewire body includes an antenna formed from a rod and a helical coil coupled together. The helical coil can have multiple windings without any gaps between the windings. The rod passes through the windings of the helical coil and is coupled to the helical coil using a conductive joint positioned at an end of the rod and at an end of the helical coil. Insulation can be positioned between the rod and the windings of the helical coil. The configuration allows visibility of the antenna along the length of a rod, except where it enters the windings of the coil. Thus, the tip visibility is enhanced as being separated from the rod.Type: ApplicationFiled: January 4, 2012Publication date: October 17, 2013Applicant: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVInventors: Merdim Sonmez, Ozgur Kocaturk, Christina E. Saikus
-
Publication number: 20130243769Abstract: Disclosed is a hetero-bifunctional ligand for use in inducing internalization of a target receptor. The hetero-bifunctional ligand includes a target receptor-binding agent that specifically binds the target receptor linked to an internalizing receptor-binding agent that specifically binds to an internalizing receptor, where the two binding agents are non-identical. Also disclosed is a method of inducing the internalization of a target receptor on a cell. The method includes contacting a cell with a hetero-bifunctional ligand, where binding of the hetero-bifunctional ligand induces internalization of a target receptor of the cell. Also disclosed is a method of treating a disease or condition associated with a target receptor using the disclosed hetero-bifunctional ligand and pharmaceutical compositions including a hetero-bifunctional ligand.Type: ApplicationFiled: April 15, 2013Publication date: September 19, 2013Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVInventor: The United States of America,as represented by the Secretary, Department of Health and Human Services
-
Publication number: 20130186173Abstract: A device and method for simulating a blast shock wave of the type produced by explosive devices such as bombs. A pneumatic charge releases a blast shock wave along a conduit which terminates in a first outlet that communicates with the atmosphere and a second outlet that is sealed to a specimen chamber. The first outlet has a quick release valve that prevents venting of the pneumatic charge to the atmosphere until the pressure at the valve reaches a predetermined level that opens the valve. The pneumatic charge therefore initially flows through the second outlet to direct the blast into the specimen chamber, until subsequent opening of the quick release valve redirects the gas flow out of the first outlet and rapidly reduces pressure in the chamber. The blast wave closely simulates the Friedlander curve, and its effects are viewed during instead of only after the blast is completed.Type: ApplicationFiled: January 23, 2013Publication date: July 25, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventor: The United States of America, as represented by the Secretary, Department of Health and Human Services
-
Publication number: 20130143966Abstract: The use of sterculic acid, and the pharmaceutically acceptable salt forms thereof, described for the treatment of inflammation, in particular, 7-ketocholesterol induced inflammation, 7-keto-cholesterol toxicity, and unregulated angiogenesis.Type: ApplicationFiled: June 24, 2011Publication date: June 6, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Ignacio R. Rodriguez, Jiahn-Dar Huang, Juan A. Amaral, Jung Wha Lee, William Samuel, Ignacio Marcos Larrayoz
-
Publication number: 20130109619Abstract: A peptide or peptidomimetic comprising an amino acid sequence based on conserved regions of IL10 or IFN-gamma receptor sequences, and related compounds and compositions, as well as methods for the use thereof to inhibit cytokine signaling.Type: ApplicationFiled: May 11, 2011Publication date: May 2, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Nadya I. Tarasova, Giorgio Trinchieri, Howard A. Young, C. Andrew Stewart, Marco A. Cardone, Alan O. Perantoni
-
Publication number: 20130039886Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.Type: ApplicationFiled: March 11, 2011Publication date: February 14, 2013Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, The University of Birmingham, of EdgbastonInventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr Illarionov, Gurdyal S. Besra
-
Publication number: 20120320458Abstract: Polarizers and polarizing beam splitter include one or more pairs of axicons that are configured to separate an input beam into a radially polarized component and a tangentially (or azimuthally) polarized component. A second axicon pair can be provided to recombine the tangentially polarized component so as to provide a more uniform beam intensity. The radially polarized component can be reflected or otherwise directed so that one or both the radial and tangential components are available for use.Type: ApplicationFiled: February 22, 2011Publication date: December 20, 2012Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVInventor: Jay R. Knutson
-
Publication number: 20120142624Abstract: Methods for determining whether a cancer patient is likely to benefit from treatment with a taxane compound based on Akt-Ser473 phosphorylation status are provided, together with kits for determining Akt-Ser473 phosphorylation status and methods for improving treatment of a cancer patient that include obtaining a determination of the Akt-Ser473 phosphorylation status of the cancer.Type: ApplicationFiled: May 21, 2010Publication date: June 7, 2012Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Sherry X. Yang, Sandra M. Swain
-
Publication number: 20120068699Abstract: A phantom calibration body (12) for calibrating diffusion MRI device (16) that mimics a material such as a mammalian tissue is disclosed. The phantom calibration body (12) includes a homogeneous aqueous solution (30) that contains a mixture of low molecular-weight and high molecular-weight polymers housed in a container (14) that is placed in the diffusion MRI device (16) for obtaining one or more diffusion MRI images of the phantom calibration body (12). A measure of diffusivity is calculated for each of the one or more diffusion MRI images in order to calibrate the diffusion MRI device. Methods of using the phantom calibration body (12) to calibrate diffusion MRI device (16) are also disclosed.Type: ApplicationFiled: January 26, 2010Publication date: March 22, 2012Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Ferenc Horkay, Carlo Pierpaoli, Peter J. Basser
-
Publication number: 20110282060Abstract: The invention described herein provides for novel nitric oxide-releasing polymers that comprise at least two adjacent units derived from acrylonitrile monomer units and containing at least one carbon-bound diazeniumdiolate. The diazeniumdiolated acrylonitrile-derived polymers can be used in medical devices therapeutically. Accordingly, the invention also provides a method of treating a biological disorder and a method of promoting angiogenesis that includes administering a medical device comprising a nitric oxide-releasing polymer comprising at least two adjacent units of acrylonitrile before exposure to nitric oxide and at least one nitric oxide releasing N2O2? group, wherein the N2O2? group is attached directly to the polyacrylonitrile backbone, to a specific location on or within the mammal in an amount effective to treat the biological disorder or promote angiogenesis.Type: ApplicationFiled: May 19, 2011Publication date: November 17, 2011Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Joseph A. Hrabie, Frank DeRosa, Larry K. Keefer
-
Publication number: 20110195064Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for diffuse large B cell lymphoma (DLBCL) patients.Type: ApplicationFiled: June 5, 2009Publication date: August 11, 2011Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Arizona Bloard of Regents on behalf of the University of Arizona, Queen Mary and Westfiled College, University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic, Universitat De Barcelona, British Columbia Cancer Agency Branch, Julius-Mazimilians-University of WuerzburgInventors: Lisa Rimsza, Andrew T. Lister, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaloy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
-
Publication number: 20110052530Abstract: The invention provides a method of promoting regression of a cancer in a mammal comprising (i) culturing autologous T cells; (ii) expanding the cultured T cells; (iii) administering to the mammal nonmyeloablative lymphodepleting chemotherapy; and (iv) after administering nonmyeloablative lymphodepleting chemotherapy, administering to the mammal the expanded T cells, wherein the T cells administered to the mammal are about 19 to about 35 days old and have not been screened for specific tumor reactivity, whereupon the regression of the cancer in the mammal is promoted.Type: ApplicationFiled: August 26, 2010Publication date: March 3, 2011Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Mark E. Dudley, Steven A. Rosenberg
-
Publication number: 20090162390Abstract: Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These chimeric polypeptides behave as molecular scaffolds which are capable of presenting the various heterologous HIV-1 epitopes. The invention demonstrates that a heterologous epitope recognized by the HIV-1 neutralizing antibody can be more fully exposed to neutralizing antibodies when presented within the backbone of the chimeric polypeptide than when the epitope is presented within the context of an HIV-1 backbone. Polynucleotides encoding these chimeric polypeptides are also provided. Immunogenic compositions are provided which comprise a chimeric polypeptide having at least one heterologous epitope that interacts with an HIV-1 neutralizing antibody. Immuno genie compositions comprising chimeric polynucleotides encoding the chimeric polypeptides of the invention are also provided.Type: ApplicationFiled: February 16, 2006Publication date: June 25, 2009Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, UAB Research FoundationInventors: George M. Shaw, Beatrice H. Hahn, Frederic Bibollet-Ruche, Peter D. Kwong